Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue. We show 15 historical shares outstanding datapoints in our DYN shares outstanding history coverage, used to compute DYN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DYN market cap history over the course of time is important for investors
interested in comparing DYN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DYN versus a peer is one thing; comparing
DYN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DYN can fluctuate over the course of history.
With this page we aim to empower investors researching DYN by allowing them to research the DYN market cap history. |
Free DYN Email Alerts:
Video: The Importance of Market Cap
